224 related articles for article (PubMed ID: 19815062)
21. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
[TBL] [Abstract][Full Text] [Related]
22. Is bicarbonate buffer suitable as a dissolution medium?
Boni JE; Brickl RS; Dressman J
J Pharm Pharmacol; 2007 Oct; 59(10):1375-82. PubMed ID: 17910812
[TBL] [Abstract][Full Text] [Related]
23. An innovative floating gastro retentive dosage system: formulation and in vitro evaluation.
Sauzet C; Claeys-Bruno M; Nicolas M; Kister J; Piccerelle P; Prinderre P
Int J Pharm; 2009 Aug; 378(1-2):23-9. PubMed ID: 19465095
[TBL] [Abstract][Full Text] [Related]
24. Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks.
Saal C; Petereit AC
Eur J Pharm Sci; 2012 Oct; 47(3):589-95. PubMed ID: 22885099
[TBL] [Abstract][Full Text] [Related]
25. Estimating drug solubility in the gastrointestinal tract.
Dressman JB; Vertzoni M; Goumas K; Reppas C
Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
[TBL] [Abstract][Full Text] [Related]
26. Estimating the maximal solubility advantage of drug salts.
Skrdla PJ
Int J Pharm; 2021 Feb; 595():120228. PubMed ID: 33484924
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices.
Lehto P; Aaltonen J; Niemelä P; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
Int J Pharm; 2008 Nov; 363(1-2):66-72. PubMed ID: 18675891
[TBL] [Abstract][Full Text] [Related]
28. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts.
He Y; Ho C; Yang D; Chen J; Orton E
J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596
[TBL] [Abstract][Full Text] [Related]
29. The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs.
Schwebel HJ; van Hoogevest P; Leigh ML; Kuentz M
Pharm Dev Technol; 2011 Jun; 16(3):278-86. PubMed ID: 20214530
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
31. Plasma profiles of lycopene after single oral and intravenous administrations in dogs.
Vertzoni M; Valsami G; Reppas C
J Pharm Pharmacol; 2006 Sep; 58(9):1211-7. PubMed ID: 16945179
[TBL] [Abstract][Full Text] [Related]
32. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.
Vertzoni M; Dressman J; Butler J; Hempenstall J; Reppas C
Eur J Pharm Biopharm; 2005 Aug; 60(3):413-7. PubMed ID: 15893920
[TBL] [Abstract][Full Text] [Related]
33. Importance of critical micellar concentration for the prediction of solubility enhancement in biorelevant media.
Ottaviani G; Wendelspiess S; Alvarez-Sánchez R
Mol Pharm; 2015 Apr; 12(4):1171-9. PubMed ID: 25665011
[TBL] [Abstract][Full Text] [Related]
34. Solution-mediated phase transformation: significance during dissolution and implications for bioavailability.
Greco K; Bogner R
J Pharm Sci; 2012 Sep; 101(9):2996-3018. PubMed ID: 22213419
[TBL] [Abstract][Full Text] [Related]
35. Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
Berben P; Ashworth L; Beato S; Bevernage J; Bruel JL; Butler J; Dressman J; Schäfer K; Hutchins P; Klumpp L; Mann J; Nicolai J; Ojala K; Patel S; Powell S; Rosenblatt K; Tomaszewska I; Williams J; Augustijns P
Eur J Pharm Biopharm; 2019 Jul; 140():141-148. PubMed ID: 31051249
[TBL] [Abstract][Full Text] [Related]
36. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability.
Ghebremeskel AN; Vemavarapu C; Lodaya M
Int J Pharm; 2007 Jan; 328(2):119-29. PubMed ID: 16968659
[TBL] [Abstract][Full Text] [Related]
37. Dissolution and pharmacokinetics of baicalin-polyvinylpyrrolidone coprecipitate.
Li B; He M; Li W; Luo Z; Guo Y; Li Y; Zang C; Wang B; Li F; Li S; Ji P
J Pharm Pharmacol; 2013 Nov; 65(11):1670-8. PubMed ID: 24111594
[TBL] [Abstract][Full Text] [Related]
38. Method for screening of solid dispersion formulations of low-solubility compounds--miniaturization and automation of solvent casting and dissolution testing.
Shanbhag A; Rabel S; Nauka E; Casadevall G; Shivanand P; Eichenbaum G; Mansky P
Int J Pharm; 2008 Mar; 351(1-2):209-18. PubMed ID: 18054181
[TBL] [Abstract][Full Text] [Related]
39. Dual Level Statistical Investigation of Equilibrium Solubility in Simulated Fasted and Fed Intestinal Fluid.
Ainousah BE; Perrier J; Dunn C; Khadra I; Wilson CG; Halbert G
Mol Pharm; 2017 Dec; 14(12):4170-4180. PubMed ID: 29072917
[TBL] [Abstract][Full Text] [Related]
40. Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base.
Hecq J; Deleers M; Fanara D; Vranckx H; Boulanger P; Le Lamer S; Amighi K
Eur J Pharm Biopharm; 2006 Nov; 64(3):360-8. PubMed ID: 16846725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
